Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590204 | 0.86 | GPR119 (1.00) | GPR119 | |
| SCHEMBL2587091 | 0.80 | GPR119 (1.00) | GPR119KDM4EALDH1A1HPGD | |
| SCHEMBL2590741 | 0.79 | GPR119 (1.00) | GPR119KDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL2590656 | 0.79 | GPR119 (0.77) | GPR119 | |
| SCHEMBL7273949 | 0.78 | SMN1; SMN2 (0.66) | GPR119SMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2592010 | 0.78 | GPR119 (0.72) | GPR119 | |
| SCHEMBL10773520 | 0.78 | NPC1 (0.53) | GPR119SMN1; SMN2KDM4ENPC1ALDH1A1 | |
| SCHEMBL10773509 | 0.76 | NPC1 (0.53) | GPR119SMN1; SMN2KDM4ENPC1ALDH1A1 | |
| SCHEMBL11568322 | 0.75 | SMN1; SMN2 (0.59) | GPR119SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL10519493 | 0.74 | GPR119 (0.64) | GPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772323-B2 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | claimed |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | claimed |
| EP-2566864-A2 | PYRIDAZINONES AS GPR119 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-13 | — | — | EP | claimed |
| WO-2011138427-A2 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | WO | claimed |
| US-8772323-B2 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| EP-2566864-A2 | PYRIDAZINONES AS GPR119 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138427-A2 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | WO | disclosed |
| EP-0196005-B1 | PYRIDAZINONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1989-12-20 | — | — | EP | disclosed |
| EP-0196005-A1 | Pyridazinones, their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | GPR65, GPR119, GPR55 | GPR119 2/4885SMN1; SMN2 3910/4885KDM4E 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.